// App-Quantinova.ai

1894 : Genetic Phenotypes Impacting Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant FMF, TRAPS and Hids/Mkd: Results from Cluster Study

Researchers

Presenter

  • Fabrizio De Benedetti

Principal Investigators

  • Paivi Miettunen

  • Tilmann Kallinich

  • Gerd Horneff

  • Riva Brik

  • Alberto Tomassini

  • Takahiro Yasumi

  • Sinisa Savic

  • Ivan Foeldvari

  • Liora Harel

  • Romina Gallizzi

  • Antonio Speziale

  • Guido Junge

  • Marco Gattorno

Medical Centers

  • Division of Rheumatology, IRCCS Bambino Gesù Children's Hospital, Rome, Rome, Italy

  • Alberta Childrens Hospital Research Institute, University of Calgary, Calgary, AB, Canada

  • Charite-University Medicine Berlin, Berlin, Germany

  • Asklepios Klinik St. Georg, Hamburg, Germany

  • Pediatric Rheumatology, Rambam Medical Center, Haifa, Israel

  • Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy

  • Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan

  • University of Leeds, Leeds, United Kingdom

  • Hamburger Zentrum fur Kinder-und Jugend rheumatologie, Hamburg, Germany

  • Schneider Children's Medical Center of Israel, Sackler Faculty of Medicine Tel Aviv University, Petach Tikvah, Israel

  • Department of Paediatrics, University of Messina, Messina, Italy

  • Novartis AG, Basel, Switzerland

  • Pediatry, G. Gaslini Institute, Genova, Italy

Locations

  • Italy

  • Canada

  • Germany

  • Israel

  • Japan

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • N/A

Biomarkers

  • TNF Receptor Superfamily Member 1A

Drug/Treatment

  • canakinumab (SC)

  • Colchicine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • NCT02059291

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved